MD Anderson Cancer Center and Xilis formed a strategic collaboration to use Xilis’ proprietary MicroOrganoSphere technology in support of preclinical research to accelerate the development of novel cancer therapies.
At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).
